Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression
Zhixiang Chen, Mi Wang, Dimin Wu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5275-5304
Closed Access | Times Cited: 14

Showing 14 citing articles:

Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy
Dize Zhang, Bohan Ma, Donghua Liu, et al.
EBioMedicine (2024) Vol. 105, pp. 105212-105212
Open Access | Times Cited: 6
p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer
Jie Luo, Zhixiang Chen, Yuanyuan Qiao, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 5
Simplified Maxwell-Boltzmann-Hansch Function (SMBH function) and its Application in PROTAC
Xuan Cao, Kaiyue Wu, Junfeng Qu, et al.
(2025)
Closed Access
Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9
Changwei Wang, Mi Wang, Yu Wang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 16, pp. 14125-14154
Closed Access | Times Cited: 3
Paralogue-Selective Degradation of the Lysine Acetyltransferase EP300
Xuemin Chen, McKenna C. Crawford, Ying Xiong, et al.
JACS Au (2024) Vol. 4, Iss. 8, pp. 3094-3103
Open Access | Times Cited: 2
Recent advances in dual PROTACs degrader strategies for disease treatment
Jianyu Liu, Yanzhuo Liu, Jiao Tang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 279, pp. 116901-116901
Closed Access | Times Cited: 2
Discovery of SD-436: A Potent, Highly Selective and Efficacious STAT3 PROTAC Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression
Renqi Xu, Haibin Zhou, Longchuan Bai, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 22, pp. 20495-20513
Closed Access | Times Cited: 2
CBP/p300 Degrader: A Promising Therapeutic Strategy for Treatment of Prostate Cancer and Beyond
Jiankang Hu, Yong Xu
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5272-5274
Closed Access | Times Cited: 1
Discovery of a Highly Potent PROTAC Degrader of p300/CBP Proteins for the Treatment of Enzalutamide-Resistant Prostate Cancer
Mengjun Ma, Mengyao Li, Chengwei Zhang, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 1
Paralogue-selective degradation of the lysine acetyltransferase EP300
Xuemin Chen, McKenna C. Crawford, Ying Xiong, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Discovery of an EP300 Inhibitor using Structure-based Virtual Screening and Bioactivity Evaluation
Dabo Pan, Yaxuan Huang, Dewen Jiang, et al.
Current Pharmaceutical Design (2024) Vol. 30, Iss. 25, pp. 1985-1994
Open Access
Structure-Based Design of CBP/EP300 Degraders: When Cooperativity Overcomes Affinity
Iván Cheng‐Sánchez, Katherine Gosselé, Leonardo Palaferri, et al.
JACS Au (2024) Vol. 4, Iss. 9, pp. 3466-3474
Open Access
Expanding the reaction toolbox for nanoscale direct-to-biology PROTAC synthesis and biological evaluation
Rebecca Stevens, Harry J. Shrives, Jenni Cryan, et al.
RSC Medicinal Chemistry (2024) Vol. 16, Iss. 3, pp. 1141-1150
Closed Access
Dysregulation of the p300/CBP histone acetyltransferases in human cancer
Longxia Xu, Hongwen Xuan, Xiaobing Shi
Epigenomics (2024) Vol. 17, Iss. 3, pp. 193-208
Closed Access
Page 1

Scroll to top